Monaco Asset Management SAM Has $135,000 Stake in Lexicon Pharmaceuticals, Inc. $LXRX

Monaco Asset Management SAM decreased its stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 66.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 117,188 shares of the biopharmaceutical company’s stock after selling 232,812 shares during the quarter. Monaco Asset Management SAM’s holdings in Lexicon Pharmaceuticals were worth $135,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. R Squared Ltd grew its position in shares of Lexicon Pharmaceuticals by 45.3% during the 4th quarter. R Squared Ltd now owns 46,579 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 14,530 shares during the period. Bank of America Corp DE grew its position in shares of Lexicon Pharmaceuticals by 80.1% during the 3rd quarter. Bank of America Corp DE now owns 57,804 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 25,707 shares during the period. Vermillion & White Wealth Management Group LLC grew its position in shares of Lexicon Pharmaceuticals by 400.0% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 26,000 shares during the period. Hudson Bay Capital Management LP acquired a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter worth approximately $26,000. Finally, Leonteq Securities AG acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Stock Performance

NASDAQ LXRX opened at $2.18 on Monday. The company has a fifty day simple moving average of $1.85 and a 200 day simple moving average of $1.55. Lexicon Pharmaceuticals, Inc. has a 12-month low of $0.62 and a 12-month high of $2.53. The company has a current ratio of 18.80, a quick ratio of 18.77 and a debt-to-equity ratio of 0.24. The company has a market cap of $968.36 million, a P/E ratio of -31.14 and a beta of 1.06.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $0.00 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.04. Lexicon Pharmaceuticals had a negative net margin of 37.46% and a negative return on equity of 18.64%. The business had revenue of $21.10 million during the quarter, compared to the consensus estimate of $9.79 million. Sell-side analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.17 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LXRX has been the subject of several recent analyst reports. Citigroup raised their price objective on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the stock a “buy” rating in a research report on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Monday, March 23rd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $4.55.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.